After evaluating safety and efficacy data for patients transfused in the Mayo Clinic-led EAP program and other existing data, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to further expand access to convalescent plasma for the treatment of COVID-19 in hospitalized patients..